Parthasarthy Rengarajan, an ear, nose, and throat surgeon in Bangalore, walks out of his clinic after seeing over 30 patients, flashes a smile, and gets ready to drive back home. No one would guess that the 57-year-old doctor was diagnosed 18 months ago with a deadly form of cancer—an aggressive brain tumor called glioblastoma multiforme.

Having lost all hope with standard treatment, he decided to try a new, experimental treatment being tested locally—and it worked so well that Dr. Rengarajan was back to operating on others in no time.

"I am over 80 percent fit with no trace of any recurrence yet," he says. Dr. Rengarajan and scores of others with terminal cancer have survived far beyond the time physicians gave them, thanks to a new technology called Rotational Field Quantum Magnetic Resonance.

RFQMR is similar to conventional MRI (magnetic resonance imaging) but functions very differently in the way it attacks tumors. Since there was no control group in its Phase I trial, and therefore no measure of how RFQMR results compare to conventional therapy, hard comparative data won’t emerge until the Phase II trial. However, the new therapy surpasses what chemotherapy and radiation can do in curing sufferers, a proponent contends. What’s more, it costs only a quarter of what chemo costs, says Rajah Vijay Kumar, the chief scientific officer at Scalene Cybernetics’ Center for Advanced Research and Development. . . .

The Cytotron’s intellectual property is protected under a Patent Cooperation Treaty application and remains the only device in existence, according to Mr. Kumar, to use nuclear resonance for in-vivo tissue engineering. The multi-frequency beams that emanate from the device range from 400 hertz to 100 kilohertz. It works on the principle that each living and non-living structure has a certain natural frequency and when two objects with similar frequencies come near each other they can communicate without physical touch. Thus, the tumor cells can be given instructions to activate their normal cell cycle of apoptosis, or programmed cell death.

So far, 106 terminally ill cancer patients have been treated: 60 percent are still alive and 30 percent of them have gone back to work and normal lives. "Patients who died had severe complications from chemotherapy and radiation and did not have time to respond to our treatment," says Dr. Vasishta, the principal investigator in the study.